---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-013038"
form_type: "8-K"
ticker: "ZVSA"
cik: "0001859007"
company_name: "ZyVersa Therapeutics, Inc."
filed_at: "2025-05-30T23:59:59+00:00"
generated_at: "2026-05-20T04:51:13.198717+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Zyversa receives Nasdaq delisting notice for low bid price; will appeal

## Summary
- Received Nasdaq letter on May 27, 2025 for non-compliance with $1.00 minimum bid price rule.
- Ineligible for cure period due to two reverse stock splits in past two years (1:35 Dec 2023, 1:10 Apr 2024).
- Unless appeal requested by June 3, 2025, securities face delisting on June 5, 2025.
- Company intends to appeal and request hearing, which will stay delisting pending panel decision.
- No assurance of regaining compliance with continued listing requirements.

## SEC filing metadata
- accession: 0001641172-25-013038
- form_type: 8-K
- ticker: ZVSA
- cik: 0001859007
- company_name: ZyVersa Therapeutics, Inc.
- filed_at: 2025-05-30T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1859007/000164117225013038/0001641172-25-013038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1859007/000164117225013038/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-013038
- JSON: https://secwatch.observer/filing/0001641172-25-013038.json
- Plain text: https://secwatch.observer/filing/0001641172-25-013038.txt

## Key facts
- Listing & Compliance Notices
  ZyVersa Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: May 27, 2025, Zyversa Therapeutics, Inc. (the “Company”) received a letter (the “Minimum Bid Price Deficiency Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Capital Market Stock Exchange (“Nasdaq”) notifying the Company that because the Company’s common stock had a closing bid price of less than $1.00 for 30 consecutive business days immediately preceding the Minimum Bid Price Deficiency Letter, the Company is not in compliance with Listing Rule 5550(a)(2) (the “Rule”). Typically, a company would be afforded a 180-calendar day period to demonstrate compliance w
  evidence_url: https://www.sec.gov/Archives/edgar/data/1859007/000164117225013038/0001641172-25-013038-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.